Back to search results

Screening for Alzheimer's Disease Studies

This study is a pre-screening process to see if you might be a good fit for future Alzheimer's disease (AD) studies sponsored by Roche. It involves a blood draw to measure pTau217 (a protein linked to AD) and a cognitive test called the ISLT to assess your memory and thinking skills. The main goal is to see the levels of pTau217 in your blood and your ISLT score on the first day. You can join if you are 50 to 90 years old and are willing to participate in future interventional AD studies. The study plans to enroll 80,000 people.

Study design
This is an interventional study with a planned enrollment of 80,000 participants. It is a screening study to determine eligibility for other Roche Alzheimer's disease studies.
What's involved
Participants will have their blood drawn and complete a cognitive test (ISLT) on Day 1.
Compensation
Not stated in the trial record.
Follow-up
Measurements for the primary endpoints are taken on Day 1.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07177352

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Recruiting
PHASE3Ages 50–90InterventionalScreening
Hoffmann-La Roche
~80,000 participants
Updated 2026-08-21 on ClinicalTrials.gov
What's tested:No Intervention

At a glance

Recruiting sites
205 of 212 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Concentration of pTau217 in Blood on Day1
Measured over Day 1
+1 more outcome measured

Conditions

Alzheimers Disease

Explore related trials

Alzheimer's DiseaseDementiaMild cognitive disorder

Where it's being run

212 sites across 57 states
Japan21
Poland21
China14
Florida13
South Korea11
Spain11
Ontario10
Texas9

Study leadership

  • Clinical Trials · STUDY_DIRECTOR · Hoffmann-La Roche

Who to contact

Reference Study ID Number: WP45722 https://forpatients.roche.com/ No attachments to email below.
[email protected]
888-662-6728 (U.S. and Canada)
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ability and willingness to participate in an interventional clinical study, including meeting key eligibility criteria of linked interventional Roche AD studies (e.g., specific age ranges)
Ability and willingness to receive information about potential eligibility in an associated interventional Roche AD study

Exclusion

Dependency in basic activities of daily living (bADLs) due to cognitive impairment
Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted)
Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD
History of severe, clinically significant central nervous system trauma
Any serious medical condition that precludes a participant's safe participation and completion of a clinical study
For participants with a clinical diagnosis of MCI or mild AD: Previous AD diagnosis based on biomarker confirmation with an approved or validated rule in method (e.g., amyloid PET or cerebrospinal fluid, blood biomarker) is exclusionary

What this trial measures

  • Concentration of pTau217 in Blood on Day1Day 1
  • Cognitive score in ISLT on Day 1Day 1